Current market catalysts

Draganfly Announces Selection As Qualified Supplier Under Government Of Canada's Defence Drone Initiative Marketplace

8-K filing — MARKEL GROUP INC. (MKL)

Filed: 2026-09-08 AccNo: 0001096343-26-000074 Size: 195 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits

Wegovy for Overweight Young Children: Novo Nordisk’s Obesity Drug Shows Effectiveness

Novo Nordisk Phase 3 STEP Young trial shows once-weekly semaglutide reduced BMI in 40.4% of children with obesity after 68 weeks.

8-K filing — La Rosa Holdings Corp. (LRHC)

Filed: 2026-09-08 AccNo: 0001213900-26-097860 Size: 1 MB Item 3.03: Material Modifications to Rights of Security Holders Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

Can Fite Biofarma H1 EPS $(1.24) Beats $(1.43) Estimate, Sales $202.000K, Same YoY

Can Fite Biofarma (AMEX:CANF) reported quarterly losses of $(1.24) per share which beat the analyst consensus estimate of $(1.43) by 13.29 percent. This is a 71.1 percent increase over losses of $(4.29) per share from

8-K filing — Rimini Street, Inc. (RMNI)

Filed: 2026-09-08 AccNo: 0001635282-26-000062 Size: 183 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 9.01: Financial Statements and Exhibits

'Kazakhstan suspends proceedings to recover $5 bln from the NCOC oil consortium, IFX reports' - Reuters

https://www.reuters.com/business/energy/kazakhstan-suspends-proceedings-recover-5-bln-ncoc-oil-consortium-ifx-reports-2026-09-08/

Orion Energy Systems Announces Additional Deployment Of MPHL2 LED Lightning Solution For Data-Center Operators

'Xerox Shareholder Pushes for Activist Changes at Company' - Bloomberg

https://www.bloomberg.com/news/articles/2026-09-08/xerox-shareholder-pushes-for-activist-changes-at-company

Roth Capital Initiates Coverage On Tempus AI with Neutral Rating, Announces Price Target of $67

Roth Capital analyst Jamie Clark initiates coverage on Tempus AI (NASDAQ:TEM) with a Neutral rating and announces Price Target of $67.

8-K filing — FIRST CITIZENS BANCSHARES INC /DE/ (FCNCN)

Filed: 2026-09-08 AccNo: 0000798941-26-000034 Size: 786 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits

Trading Halt: Halted at 8:25:00 a.m. ET - Trading Halt: Halt News Pending

Oceaneering International Sees Preliminary FY2026 Sales $2.800B-$3.000B vs $2.909B Est

Oceaneering International (NYSE:OII) sees preliminary FY2026 sales of $2.800 billion-$3.000 billion vs $2.909 billion analyst estimate.

BMO Capital Maintains Market Perform on Ionis Pharmaceuticals, Lowers Price Target to $54

BMO Capital analyst David Lebowitz maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Market Perform and lowers the price target from $61 to $54.

Rothschild & Co Initiates Coverage On Natera with Buy Rating, Announces Price Target of $385

Rothschild & Co analyst Jamie Clark initiates coverage on Natera (NASDAQ:NTRA) with a Buy rating and announces Price Target of $385.

BMO Capital Maintains Outperform on CMS Energy, Lowers Price Target to $77

BMO Capital analyst James Thalacker maintains CMS Energy (NYSE:CMS) with a Outperform and lowers the price target from $82 to $77.

Can-Fite BioPharma Says Blinded Overall Survival In Pivotal Phase 3 Namodenoson Liver Cancer Study Appears Longer Than Originally Anticipated; Evaluating Earlier Timing For Planned Interim Analysis

JP Morgan Upgrades Magnolia Oil & Gas to Overweight, Raises Price Target to $33

JP Morgan analyst Arun Jayaram upgrades Magnolia Oil & Gas (NYSE:MGY) from Neutral to Overweight and raises the price target from $32 to $33.

Lexaria Bioscience Announces Warrant Inducement Repricing 453,969 Warrants To $12.92/Share From Original Prices Of $17.85 To $45.90, For About $5.9M Gross Proceeds; Issues New Series A, Series B Warrants At $12.67/Share

GRI Bio Says Phase 2a GRI-0621 IPF Study Showed Placebo-Adjusted FVC Change Of +99 mL At Week 12, +139 mL On Background Antifibrotic Therapy; Says Data Supports Advancement Into Longer-Duration Study

Sensata Technologies Introduces OmniNode

Sensata’s new OmniNode simplifies commercial EV power distribution architecture by consolidating multiple high-voltage components into a single system.Integrates switching, protection, sensing, diagnostics,

JP Morgan Downgrades Gulfport Energy to Underweight, Lowers Price Target to $194

JP Morgan analyst Zach Parham downgrades Gulfport Energy (NYSE:GPOR) from Overweight to Underweight and lowers the price target from $240 to $194.

8-K filing — VERU INC. (VERU)

Filed: 2026-09-08 AccNo: 0001193125-26-384430 Size: 202 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits

Rothschild & Co Initiates Coverage On Guardant Health with Buy Rating, Announces Price Target of $203

Rothschild & Co analyst Jamie Clark initiates coverage on Guardant Health (NASDAQ:GH) with a Buy rating and announces Price Target of $203.

FDA Approves Abbott’s TactiFlex Duo Ablation Catheter, Sensor Enabled To Treat Patients With Challenging Cases Of Atrial Fibrillation

Abbott's TactiFlex™ Duo Ablation Catheter, Sensor Enabled™ combines pulsed field ablation (PFA) and radiofrequency (RF) energy in a single catheter to treat complex atrial fibrillation (AFib) casesStrong clinical

8-K filing — GRI Bio, Inc. (GRI)

Filed: 2026-09-08 AccNo: 0001824293-26-000057 Size: 4 MB Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits

8-K filing — Parker-Hannifin Corp (PH)

Filed: 2026-09-08 AccNo: 0001193125-26-384428 Size: 142 KB Item 8.01: Other Events

S&P 500’s ‘Teflon’ Streak Has Reached 329 Sessions — Wall Street Warns These Risks Could Finally Break the Market

Despite the S&P 500's historic 329-session streak, HSBC and Deutsche Bank warn that stagflation and leverage threaten this "Teflon" market.

BMO Capital Downgrades Amgen to Market Perform, Maintains Price Target to $450

BMO Capital analyst Evan David Seigerman downgrades Amgen (NASDAQ:AMGN) from Outperform to Market Perform and maintains the price target from $450 to $450.

8-K filing — AGILENT TECHNOLOGIES, INC. (A)

Filed: 2026-09-08 AccNo: 0001193125-26-384426 Size: 186 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits